Drug makers entered 2017 fearing the worst about retaining their US pricing power. They exited the year more jubilant, since on most measures, 2017 delivered a resurgence for pharma and biotech. The picture was similar for the medical technology industry, though life got tougher for the smaller groups.
Our report offers analysis and expert commentary on M&A deals, venture financing, initial public offerings and FDA approvals in the pharma and medtech sectors during 2017.
All major healthcare indices climbed in 2017, echoing wider stock market strength
The $80bn spent on pharma & biotech acquisitions in 2017 makes it the slowest M&A year of the past five
With two record-breaking final quarters under its belt 2017 was a huge year for biotech venture funding
In medtech, the total value of all mergers closed in 2017 came in just shy of $100bn
